APTO vs. TIL, PASG, AVRO, CVM, CRIS, IKNA, TSBX, GNTA, CRTX, and TARA
Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include Instil Bio (TIL), Passage Bio (PASG), AVROBIO (AVRO), CEL-SCI (CVM), Curis (CRIS), Ikena Oncology (IKNA), Turnstone Biologics (TSBX), Genenta Science (GNTA), Cortexyme (CRTX), and Protara Therapeutics (TARA). These companies are all part of the "medical" sector.
Aptose Biosciences (NASDAQ:APTO) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends, valuation and community ranking.
Instil Bio is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.
Aptose Biosciences has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Comparatively, Instil Bio has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500.
26.6% of Aptose Biosciences shares are owned by institutional investors. Comparatively, 60.6% of Instil Bio shares are owned by institutional investors. 4.6% of Aptose Biosciences shares are owned by insiders. Comparatively, 46.5% of Instil Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Instil Bio's return on equity of -51.27% beat Aptose Biosciences' return on equity.
Aptose Biosciences received 282 more outperform votes than Instil Bio when rated by MarketBeat users. Likewise, 65.73% of users gave Aptose Biosciences an outperform vote while only 52.51% of users gave Instil Bio an outperform vote.
In the previous week, Aptose Biosciences and Aptose Biosciences both had 3 articles in the media. Instil Bio's average media sentiment score of 1.25 beat Aptose Biosciences' score of 0.94 indicating that Instil Bio is being referred to more favorably in the news media.
Aptose Biosciences currently has a consensus price target of $17.50, indicating a potential upside of 1,435.09%. Instil Bio has a consensus price target of $25.00, indicating a potential upside of 129.78%. Given Aptose Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Aptose Biosciences is more favorable than Instil Bio.
Summary
Aptose Biosciences beats Instil Bio on 9 of the 14 factors compared between the two stocks.
Get Aptose Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptose Biosciences Competitors List
Related Companies and Tools
